As a nation, we are able to advance efforts to end the HIV and viral hepatitis epidemics. We possess proven prevention tools, including pre-exposure prophylaxis medication (PrEP), and effective treatments. We urge you to continue your historically strong commitment and leverage this pivotal moment to support the nation’s public health by comprehensively addressing these chronic diseases. Increased investment – and certainly not cuts – in surveillance, education, prevention, and care and treatment will lead to further progress in reducing HIV and viral hepatitis and allow us to continue to hold the promise of ending these epidemics.
Request for Nevada governor to veto AB259 establishing maximum fair price limits for prescription drugs
While we support efforts to make prescription drugs more affordable, we respectfully urge you to veto Assembly Bill 259 because it would impose harmful and untested price controls without guaranteeing savings for patients. AB 259 would prohibit any entity in Nevada from purchasing or seeking reimbursement for a prescription drug at a price higher than the flawed and untested federally determined Maximum Fair Price (MFP), as established under the Inflation Reduction Act (IRA). This effectively creates a blanket price cap for all state regulated health plans, based on prices negotiated exclusively for Medicare beneficiaries.
39 groups urge USPSTF to update its 2023 HIV PrEP recommendation
We urge the U.S. Preventive Services Task Force (USPSTF) to expeditiously update its 2023 HIV Pre-Exposure Prophylaxis (PrEP) recommendation to incorporate important new evidence, including clinical trial data on lenacapavir, a new twice-yearly PrEP formulation, and new findings on PrEP’s effectiveness in women and other key populations.
Opposition to Massachusetts S.875 to Create a Prescription Drug Accountability Board
The HIV+Hepatitis Policy Institute remains committed to advancing policies that ensure access to affordable medications while fostering the development needed to fight HIV and hepatitis. We urge you to oppose S.875 and recommend exploring alternative approaches that directly address affordability without risking access or undermining medical advancements.
Support for Wisconsin SB203 to ban copay accumulators
The HIV+Hepatitis Policy Institute, a leading organization advocating for equitable and affordable healthcare for individuals living with or at risk of HIV, hepatitis, and other chronic health conditions, strongly supports the provision in Senate Bill 203 that ensures third-party copay assistance counts toward patients’ deductibles and out-of-pocket maximums.